Matthew E. Korenberg - Jan 26, 2022 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
EVP,Finance & Strategy and CFO
Signature
By: Charles S. Berkman For: Matthew E. Korenberg
Stock symbol
LGND
Transactions as of
Jan 26, 2022
Transactions value $
-$412,431
Form type
4
Date filed
1/28/2022, 07:43 PM
Previous filing
Jul 2, 2021
Next filing
Feb 16, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Award $0 +4.8K +12.1% $0.00 44.5K Jan 26, 2022 Direct F1
transaction LGND Common Stock Award $0 +6.85K +15.39% $0.00 51.3K Jan 26, 2022 Direct F2
transaction LGND Common Stock Tax liability -$150K -1.32K -2.57% $113.68 50K Jan 26, 2022 Direct F3
transaction LGND Common Stock Tax liability -$262K -2.31K -4.62% $113.68 47.7K Jan 26, 2022 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 05/29/2019 and were eligible to vest based on the Issuer achievement of certain performance objectives during the three-year performance period ending December 31, 2021. On January 26, 2022, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares.
F2 Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 03/09/2020 and were eligible to vest based on the Issuer achievement of certain performance objectives during the two-year performance period ending December 31, 2021. On January 26, 2022, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares.
F3 Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs.